Please provide your email address to receive an email when new articles are posted on . The addition of intraperitoneal paclitaxel to systemic capecitabine and oxaliplatin appeared to benefit patients ...

A retrospective study compared progression-free and overall survival of hyperthermic intraperitoneal chemotherapy with conventional intraperitoneal chemotherapy in patients with ovarian cancer.

Because cytotoxicity is one of the major hurdles in the application of many transfection agents, an important feature of our cationic liposome is its low toxicity for cells at the concentrations ...

Please provide your email address to receive an email when new articles are posted on . Adding hyperthermic intraperitoneal chemotherapy to cytoreductive surgery did not significantly prolong PFS or ...

EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the HSP90 inhibitor ganetespib with carboplatin followed by maintenance treatment with niraparib (+/- ...

Cancers originating from organs in the peritoneal cavity (e.g., ovarian, pancreatic, colorectal, gastric and liver) account for approximately 250,000 new cancer cases annually in the USA. Peritoneal ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

HIPEC surgery is a promising treatment option for patients with certain abdominal cancers. Surgical oncologist Erin Ward, MD, discusses which patients would be best candidates for HIPEC, explains why ...

Drug delivery systems can alter drug clearance from the peritoneal cavity and drug toxicity profiles. For example, IP injection of cisplatin-loaded polymeric microspheres (100–200 µm, which releases ...